Global Expansion

With its cultivation and manufacturing base domiciled in Australia, LGP is seeking to capitalise on Australia’s international reputation for high quality, trusted products borne from Australia’s leading agricultural and production practices. 

LGP has identified Germany as a highly prospective territory for market entry, as medicinal cannabis products have been approved for reimbursement through health insurance. To date, the main conditions for which applications have been approved (by number of patients) in Germany are pain, attention deficit hyperactivity disorder (ADHD), spasticity as a symptom of multiple sclerosis and palliative care.

In addition, given the current lack of a domestic supply of medicinal cannabis products in Germany, the Company considers this market to be an attractive international entry point for LGP. To the extent possible, LGP intends to leverage its know-how gained from establishing distribution in Australia to establish distribution channels for its products in Germany via proposed arrangements.

Little Green Pharma has established a German subsidiary as part of its future proposed strategy to facilitate the import and export of medicinal cannabis products under its own import licence and via contracted distribution arrangements within Germany.

Further to its business development activities, LGP recently received its first commercial order of 2,400 units to be distributed to Germany. Fulfilment of this order is expected to take place following completion of the cultivation facility expansion.